Biocon Q3 FY23 revenue up 36%

The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses

Healthcare Global Enterprises revenue up 19%

Technology and innovation play a pivotal role towards enhancing healthcare systems, increasing access to healthcare services, and reducing costs of therapies and consultations

Syngene Q3FY23 revenue reaches Rs. 803 Cr; PAT reaches Rs. 110 Cr

The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid

Biocon Q2FY23 net profit slips 10% to Rs 168 Cr; Revenue up 26%

Strong order book in CMO segments for J.B. Chemicals & Pharmaceuticals, says Prabhudas Lilladher

The company sees the business reaching $100mn

Tatva Chintan Q2 FY23 revenue down 27%; Net profit down 78%

Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%

Balaxi Pharmaceuticals delivers strong growth in Q2 FY23

Revenue is up 23% whereas Profit After Tax expands 29% for the company

Jubilant Ingrevia to invest Rs. 2,050 crore during FY 22-25

Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side

Sustaining growth momentum is key for Navin Fluorine: ICICI Securities

NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.

Syngene Q2 FY23 PAT up 11% to Rs. 102 Cr

Revenue from operations up 26% to Rs. 768 crores